Drugs / BH4
BH4
English name Tetrahydrobiopterin
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06312748 | May 2021 → Sep 2028 expected | diastolic heart failure | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1 | NCT03680573 | Jan → May 2018 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2026 overdue | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | Russell Richardson | Recruiting | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT02530996 | Jan → Jun 2016 | rheumatic disorder | VA Office of Research and Development | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT04227080 | Jun 2020 → Dec 2021 | phenylketonuria | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BH4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530996 ↗ |
| Known as | (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride | “This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.” NCT03680573 ↗ |
| Known as | KUVAN | “oral administration of 20 mg/kg KUVAN (BH4)” NCT04227080 ↗ |
| Known as | tetrahydrobiopterin | “therapeutic efficacy of the pharmacologic compound tetrahydrobiopterin (BH4) in SSc” NCT02530996 ↗ |
| Route | Oral | “Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured.” NCT02530996 ↗ |